摘要
门冬胰岛素30(诺和锐30)进入中国市场已有12年,广泛应用于临床。但是,在临床使用中,还存在使用不规范、不明确等问题,且缺乏相应的技巧指导。本文将采用问答形式,针对临床常遇到的问题,即临床使用技巧方面进行解答,以实现更好的治疗结局,对临床医师予以指导。
There has been12years since biphasic insulin aspart30(BIAsp30)came to markets in China.It has been widely used in clinics.However,there is no regulations for standard practice with biphasic insulin aspart30.This article will adopt a question-and-answer format/module todemonstrate standard practice of BIAsp30in clinics.It is noteworthy that one-on-one solution to problems frequently encountered in clinics will bediscussed thoroughly which provides detailed instruction on clinical practice and improves outcome of medication..
作者
高凌
GAO Ling(Department of Endocrinology, Renmin Hospital of Wuhan University, Wuhan Hubei 430060, China)
出处
《药品评价》
CAS
2017年第15期14-17,64,共5页
Drug Evaluation
关键词
门冬胰岛素30
临床使用
预混胰岛素
Biphasic Insulin Aspart 30
Clinical Application
Premix Insulin